1. 8-(4 (4-phenylbutoxy)benzoyl)amino-2-(tetrazol-5'-yl)-4-oxo-4h-1-benzopyran
2. Ono 1078
3. Ono-1078
4. Ono-rs 411
5. Ono-rs-411
6. Sb 205312
1. 103177-37-3
2. Azlaire
3. Ono-1078
4. Pranlukast Hydrate
5. Ono 1078
6. Sb 205312
7. Ccn 00401
8. Rs 411
9. Pranlukast (inn)
10. N-[4-oxo-2-(2h-tetrazol-5-yl)chromen-8-yl]-4-(4-phenylbutoxy)benzamide
11. Onon
12. Ono-rs-411
13. 4-oxo-8-(4-(4-phenylbutoxy)benzoylamino)-2-(tetrazol-5-yl)-4h-1-benzopyran
14. Chembl21333
15. N-(4-oxo-2-(1h-tetrazol-5-yl)-4h-chromen-8-yl)-4-(4-phenylbutoxy)benzamide
16. Ccn-00401
17. Rs-411
18. Tb8z891092
19. Ncgc00181765-01
20. Sb-205312
21. Pranlukast [inn]
22. N-(4-oxo-2-(1h-tetrazol-5-yl)-4h-1-benzopyran-8-yl)-p-(4-phenylbutoxy)benzamide
23. N-(4-oxo-2-(2h-tetrazol-5-yl)-4h-chromen-8-yl)-4-(4-phenylbutoxy)benzamide
24. 8-[4(4-phenylbutoxy)benzoyl]amino-2-(5-tetrazolyl)-4-oxo-4h-1-benzopyran;8-[4(4-phenylbutoxy)benzoyl]amino-2-(5-tetrazolyl)-4-oxo-4h-1-benzopyran
25. N-[4-oxo-2-(1h-tetrazol-5-yl)-4h-1-benzopyran-8-yl]-p-(4-phenylbutoxy)benzamide;n-[4-oxo-2-(1h-tetrazol-5-yl)-4h-1-benzopyran-8-yl]-p-(4-phenylbutoxy)benzamide
26. Azlaire (tn)
27. Pranlukast [inn:ban]
28. Sr-05000001474
29. Unii-tb8z891092
30. N-[4-oxo-2-(1h-tetrazol-5-yl)-4h-chromen-8-yl]-4-(4-phenylbutoxy)benzamide
31. N-[4-oxo-2-(2h-tetrazol-5-yl)-1-benzopyran-8-yl]-4-(4-phenylbutoxy)benzamide
32. Pranlukast [mi]
33. Pranlukast [mart.]
34. Schembl3693
35. Dsstox_cid_23782
36. Dsstox_rid_80074
37. Pranlukast [who-dd]
38. Dsstox_gsid_43782
39. Mls006010078
40. Gtpl3634
41. Ono Rs-411
42. Dtxsid3043782
43. Schembl18058592
44. Chebi:94810
45. Hms2089h16
46. Hms3650a14
47. Hms3714e03
48. Bcp04577
49. Hy-b0290
50. Zinc1542146
51. Tox21_112952
52. Ac-696
53. Bdbm50023198
54. Mfcd00864631
55. Akos015967342
56. Ccg-220661
57. Db01411
58. Sb19080
59. N-[4-oxo-2-(1h-tetrazol-5-yl)-4h-1-benzopyran-8-yl]-4-(4-phenylbutoxy)benzamide
60. As-15105
61. Smr004701229
62. Cas-103177-37-3
63. Ft-0652673
64. P2115
65. C71133
66. D08408
67. Ab01275471-01
68. 177p373
69. L013134
70. Q7238392
71. Sr-05000001474-1
72. Sr-05000001474-2
73. Sr-05000001474-3
74. Brd-k97045029-001-01-9
75. Brd-k97045029-001-04-3
76. 8-[4-(4-phenylbutyloxy)benzoyl]amino-2-(tetrazol-5-yl)-4-oxo-4h-1-benzopyran
77. Benzamide, N-(4-oxo-2-(1h-tetrazol-5-yl)-4h-1-benzopyran-8-yl)-4-(4-phenylbutoxy)-
78. N-[4-oxo-2-(1h-tetrazol-5-yl)-4h-1-benzopyran-8-yl]-4(4-phenylbutoxy)benzamide
79. N-[4-oxo-2-(1h-tetrazol-5-yl)-4h-chromen-8-yl]-4-(4-phenyl-butoxy)-benzamide
80. Benzamide, N-(4-oxo-2-(2h-tetrazol-5-yl)-4h-1-benzopyran-8-yl)-4-(4-phenylbutoxy)-
81. Knt
82. N-[4-oxo-2-(1h-tetrazol-5-yl)-4h-chromen-8-yl]-4-(4-phenyl-butoxy)-benzamide (ono-rs-411)
83. N-[4-oxo-2-(1h-tetrazol-5-yl)-4h-chromen-8-yl]-4-(4-phenyl-butoxy)-benzamide(ono-rs-411)
Molecular Weight | 481.5 g/mol |
---|---|
Molecular Formula | C27H23N5O4 |
XLogP3 | 4.2 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 9 |
Exact Mass | 481.17500423 g/mol |
Monoisotopic Mass | 481.17500423 g/mol |
Topological Polar Surface Area | 119 Ų |
Heavy Atom Count | 36 |
Formal Charge | 0 |
Complexity | 778 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Used as an adjunct to the standard therapy of inhaled steroids with inhaled long- and/or short-acting beta-agonists.
Pranlukast is a cysteinyl leukotriene receptor-1 antagonist.
Leukotriene Antagonists
A class of drugs designed to prevent leukotriene synthesis or activity by blocking binding at the receptor level. (See all compounds classified as Leukotriene Antagonists.)
Anti-Asthmatic Agents
Drugs that are used to treat asthma. (See all compounds classified as Anti-Asthmatic Agents.)
R - Respiratory system
R03 - Drugs for obstructive airway diseases
R03D - Other systemic drugs for obstructive airway diseases
R03DC - Leukotriene receptor antagonists
R03DC02 - Pranlukast
Hepatic
Pranlukast selectively antagonizes leukotriene D4 (LTD4) at the cysteinyl leukotriene receptor, CysLT1, in the human airway. Pranlukast inhibits the actions of LTD4 at the CysLT1 receptor, preventing airway edema, smooth muscle contraction, and enhanced secretion of thick, viscous mucus.
LOOKING FOR A SUPPLIER?